StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

How the market prices BioXcel Therapeutics

Each ratio against its own distribution since 2018, from month-end prices and the figures reported at the time

BioXcel Therapeutics trades at 1.1× its earnings, against a median of 30.9× since 2018 — cheaper than 100% of the months in between.

The shaded bar covers the 5th to 95th percentile of month-end values since 2018, the darker part the 25th to 75th, the line the median and the dot today. The figure on the right is the percentile today sits at.

Price to sales since 2018

Median 30.9×, today 1.1×

What BioXcel Therapeutics keeps of every dollar

Trailing twelve months, from revenue down to net income. Grey columns are what comes out.

Margins against the industry

Gross margin53.1%vs 52.8%
Operating margin-6054.7%vs -42.9%
EBITDA margin-6054.7%vs -29.3%
Net margin-9549.9%vs -39.9%
Free cash flow margin-6860.4%vs -9.41%

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it earns on the capital it uses

Trailing twelve months over average capital

Return on assets-259.6%vs -40.6%

How hard the assets work

Revenue per dollar of assets0.03vs 0.39
Inventory turns a year0.70vs 2.68
Revenue per employee$20.05Kvs $405.05K
Profit per employee-$1.92Mvs -$704.12K

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it owes and what covers it

Latest balance sheet, against twelve months of cash generation

Borrowings exceed cash by $91.61M.

Total debt$104.45M
Cash and short-term investments$12.84M
EBITDA, trailing twelve months-$44.93M
Free cash flow, trailing twelve months-$50.90M

Leverage and liquidity

Current ratio0.21vs 3.28
Quick ratio0.09vs 2.37

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

Scores and rules of thumb

Academic scores computed from the latest two fiscal years. They are screens, not verdicts.

Piotroski F-Score

Nine yes-or-no tests of profit, leverage and efficiency against last year.

3 of 9 tests passed

How the shares have traded

Total return includes reinvested dividends, to the close on Oct 19, 2026

Total return against the S&P 500

The axis is compressed: each step is ten times the one before, so a month and a decade fit on the same line.

BTAIQS&P 500
PeriodBTAIQS&P 500DifferenceBTAIQ per yearS&P 500 per year
1 month-56.9%+0.6%−57.5 pts
3 months-97.2%+3.4%−100.6 pts
Year to date-98.4%+13.3%−111.7 pts
1 year-98.9%+16.6%−115.5 pts
3 years-99.9%+86.4%−186.3 pts-91.6%+23.1%
5 years-100.0%+81.9%−181.8 pts-86.0%+12.7%

Who is betting against it

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

1M BTAIQ shares were sold short on Oct 30, 2026, down 13.5% from the previous report. At recent volumes it would take 3.3 days to buy them back.

Shares sold shortDays to cover

The last twelve reports

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20261,420,750-13.5%432,3083.3
Oct 15, 20261,641,640-16.6%440,0683.7
Sep 30, 20261,967,495-36.2%1,204,9791.6
Sep 15, 20263,084,471-49.6%28,098,1661.0

Every measure, in full

42 figures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
–
Last ex-dividend date
No dividends
Fundamentals through
Jun 30, 2026
Share price as of
–

Share statisticsIndustry

Shares Change (YoY)
389.6%
11.0%
Shares Change (QoQ)
15.6%
0.58%
Float
30M
49M
Shares Held by Insiders
3.03%
11.1%
Shares Held by Institutions
19.7%
56.3%

MarginsIndustry

Gross Margin
53.1%
52.8%
Operating Margin
-6054.7%
-42.9%
Profit Margin
-9549.9%
-39.9%
EBITDA Margin
-6054.7%
-29.3%
FCF Margin
-6860.4%
-9.41%

Returns on capitalIndustry

Return on Assets (ROA)
-259.6%
-40.6%

Financial positionIndustry

Current Ratio
0.21
3.28
Quick Ratio
0.09
2.37
Interest Coverage
-2.61
-6.08

GrowthIndustry

Revenue Growth (YoY)
-14.5%
5.81%
Revenue Growth (3Y CAGR)
19.6%
2.25%

EfficiencyIndustry

Asset Turnover
0.03
0.39
Inventory Turnover
0.70
2.68
Revenue Per Employee
$20.05K
$405.05K
Profits Per Employee
-$1.92M
-$704.12K
Employee Count
37
75

Income statement (TTM)Industry

Revenue
$742.00K
$58.79M
Gross Profit
$394.00K
$103.58M
Operating Income
-$44.93M
-$21.49M
Net Income
-$70.86M
-$22.47M
EBITDA
-$44.93M
-$17.14M
EPS (Diluted)
-$3.78
-$0.83

Balance sheetIndustry

Total Debt
$104.45M
$114.91M
Net Cash (Debt)
-$91.61M
$15.31M
Net Cash Per Share
-$2.93
$0.72
Equity (Book Value)
-$115.46M
$49.40M
Book Value Per Share
-$3.69
$1.45
Tangible Book Value
-$115.46M
$23.58M
Working Capital
-$108.45M
$74.34M

Cash flow (TTM)Industry

Operating Cash Flow
-$50.90M
-$12.15M
Capital Expenditures
$0
-$1.02M
Free Cash Flow
-$50.90M
-$20.44M
FCF Per Share
-$1.63
-$0.42

Taxes and interestIndustry

Interest Expense
$17.22M
$3.07M

Scores and fair valueIndustry

Piotroski F-Score
3
4

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?